PharmaEngine 智擎生技製藥股份有限公司

LATEST NEWS 2014/05/01 - Event PharmaEngine Announces MM-398 (PEP02) in Combination with 5-FU/LV Met the Primary Endpoint of Overall Survival in Phase 3 Post-Gemcitabine Metastatic Pancreatic Cancer Study Vision To be one of the most innovative ...

www.pharmaengine.com